CAR-T Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem
—
For more than a decade, CAR-T cell therapy has been one of oncology’s most electrifying stories — and one of its most stubbornly partial ones. The technology can cure relapsed blood cancers that once carried months-long prognoses. It is less effective against the solid tumors that kill most cancer patients. In 2026, that asymmetry is starting to crack.
A series of trial readouts in the first quarter of this year, combined with regulatory milestones and hard economics, has reshaped the field’s realistic near-term outlook. Some targets are working. The cost model for autologous therapy is increasingly recognized as a structural barrier to scale. And a race to produce viable off-the-shelf allogeneic alternatives — potentially a tenth of the price — has moved from concept to pivotal trials.
This is where CAR-T solid tumors clinical development actually stands in 2026.
—
The Three Walls
Before cataloguing what is working, it helps to understand why CAR-T solid tumors applications have resisted intervention with such consistency. Three structural barriers distinguish them from blood cancers.
First, antigen heterogeneity. CAR-T cells work by recognizing a specific protein on the surface of cancer cells. In leukemia and lymphoma, that target — CD19, for example — is expressed uniformly across malignant cells. Solid tumors are genetically chaotic. They shed surface targets under immune pressure, downregulate antigens in response to therapy, and present different antigen profiles in different regions of the same mass. A CAR-T cell that kills antigen-positive cells can leave antigen-negative subclones untouched, and those clones eventually dominate.
Second, the tumor microenvironment (TME). Even when a CAR-T cell reaches a solid tumor — itself a non-trivial feat given the dense, fibrotic stroma that physically walls off many carcinomas — it faces an immunosuppressive gauntlet. TGF-β, PD-L1, and regulatory T cells combine to exhaust T-cell function. Lactic acid from anaerobic tumor metabolism starves CAR-T cells of glucose. The result is that many cells that successfully traffic to the tumor site are rendered dysfunctional before they can kill.
Third, manufacturing cost. Autologous CAR-T — the only commercially approved form — is patient-specific. Blood is drawn, T cells are isolated, shipped to a GMP facility, engineered, expanded, quality-checked, and re-infused.
The process takes weeks and costs $400,000 to $500,000 per patient at list price. That model works, with significant reimbursement battles, for the thousands of patients per year who develop relapsed large B-cell lymphoma. Applied to the hundreds of thousands who develop gastric, lung, or colorectal cancer, the math breaks: at autologous pricing, treating the approximately 40,000 new gastric cancer cases diagnosed annually in the United States would require $16 billion in drug spend for that single indication alone. Allogeneic manufacturing targeting $50,000–$100,000 per patient is not an incremental improvement — it is the prerequisite for solid tumor cell therapy to exist at meaningful scale.
—
What Is Working: The Claudin 18.2 Breakthrough
The most significant piece of data for CAR-T solid tumors in recent months comes from CARsgen Therapeutics and its CLDN18.2-targeting therapy satri-cel, evaluated in the ClinicalTrials.gov satri-cel study (NCT03874897).
Claudin 18.2 is a tight junction protein overexpressed in gastric, gastroesophageal junction, and pancreatic cancers. It has limited expression in normal tissue, making it an attractive solid tumor target. CARsgen’s pivotal Phase 2 trial, CT041-ST-01, randomised patients with CLDN18.2-positive advanced gastric or gastroesophageal junction cancer — refractory to at least two prior lines of therapy — to receive satri-cel or physician’s choice of treatment.
The result, published in The Lancet and presented as an oral at ASCO 2025, is historic: satri-cel produced a median progression-free survival of 3.25 months versus 1.77 months on the control arm. An overall response rate of 38.8%, with no dose-limiting toxicities and no treatment-related deaths. More importantly, this is the first randomised controlled trial of CAR-T in any solid tumor to show superiority over standard of care. The bar for that achievement is not as high as it sounds — these are heavily pretreated patients with few options — but the precedent is real.
China’s National Medical Products Administration has granted satri-cel Breakthrough Therapy designation and Priority Review. The regulatory path in the United States remains open, though no US IND or NDA filing has been announced as of mid-2026.
—
Neuroblastoma, B7-H3, and the Pediatric Frontier
GD2, a ganglioside antigen expressed at high levels on neuroblastoma cells, has been a CAR-T target for years. Updated data from trials using third-generation GD2-CAR-T — incorporating both CD28 and 4-1BB co-stimulatory domains — show improvements in persistence compared to earlier constructs. Median CAR-T cell persistence of three months, with two patients showing circulating cells beyond two years, exceeds what previous solid tumor trials have reported. The challenge with GD2 is its expression on peripheral nerves, which creates a neurotoxicity risk as doses escalate.
B7-H3 (CD276) is emerging as a broader target for CAR-T solid tumors. The protein is overexpressed on lung, prostate, pancreatic, and brain tumors, with relatively low normal tissue expression. In March 2026, a novel B7-H3-targeting CAR-T construct developed at Washington University in St. Louis received FDA Breakthrough Therapy designation — a signal that preliminary data were compelling enough for the agency to engage closely with development. Full Phase I data are expected later this year.
CD70, meanwhile, has attracted interest in renal cell carcinoma. One patient in the COBALT trial — using an allogeneic CD70-specific CAR-T — achieved a complete response that has remained durable beyond 18 months, a notable outcome in an indication with few good options after first-line therapy. CD70 is particularly interesting because it marks not only tumor cells but also cancer-associated fibroblasts (CAFs), the stroma-building cells that contribute to TME barrier formation — making it a potential dual-action target.
—
Adjacent Approaches: What TIL and TCR-T Therapies Teach CAR-T
Two approved cellular therapies for solid tumors deserve close attention, even though neither is a CAR-T construct. Their regulatory and commercial success contains a lesson about how to work around the antigen targeting problem — parallel to what we documented in our analysis of mRNA cancer vaccine Phase 3 regulatory submissions and clinical endpoint hurdles in novel biotech drug discovery trials.
Iovance Biotherapeutics’ lifileucel (AMTAGVI), which received FDA approval for advanced melanoma, is a tumor-infiltrating lymphocyte therapy. Rather than engineering T cells to recognize a single specific antigen, TIL therapy harvests polyclonal T cells already present in a patient’s tumor — cells that the patient’s immune system has already directed toward cancer cells — expands them massively ex vivo, and re-infuses them. This approach sidesteps the antigen heterogeneity problem because TIL cells collectively recognize a diverse array of tumor targets.
The FDA granted accelerated approval in February 2024 for unresectable or metastatic melanoma. By Q4 2025, Iovance was reporting 30% quarterly revenue growth and approaching 50% gross margins; early sarcoma data (50% ORR in six evaluable patients) support a registrational trial beginning in 2026. Personalized neoantigen approaches — including the mRNA cancer vaccines now in Phase 3 trials — extend this complementary immunotherapy logic further still.
Adaptimmune’s afamitresgene autoleucel (Tecelra) takes a different bypass route: T-cell receptor (TCR) engineering rather than chimeric antigen receptor design. TCR-T cells recognize intracellular antigens presented on MHC molecules, expanding the targetable antigen space beyond surface proteins.
Approved in August 2024 for synovial sarcoma based on 39% ORR and a median overall survival of approximately 17 months against a historical benchmark of less than 12 months, Tecelra is the first FDA-approved engineered cell therapy for a solid tumor. Seventy percent of responders remained alive at two years. The lesson for CAR-T developers: durable responses in narrow, well-defined patient populations — identified by biomarker (HLA type, MAGE-A4 expression) — can clear the regulatory bar even without randomised data.
—
The Off-the-Shelf Race
The biggest structural shift in CAR-T solid tumors over the next three to five years will not come from which antigen CAR-T cells target. It will come from who makes them, and how.
The proposed solution is allogeneic, or “off-the-shelf,” CAR-T. Donor T cells are collected once from a healthy volunteer, engineered to express the CAR construct and to resist immune rejection, expanded into a master cell bank, and subdivided into hundreds of patient doses. When a patient needs treatment, a vial is thawed and infused.
The engineering obstacles are real. Donor T cells must be stripped of their native T-cell receptor (TCR) to prevent graft-versus-host disease, and the patient must be lymphodepleted to create space for donor cells that the host immune system will otherwise reject within days. Several platforms address this differently:
Allogene Therapeutics uses TALEN gene editing, partnering with Cellectis’ intellectual property. Their lead asset cema-cel showed strong interim data at AACR 2026: in a 24-patient slice of the Phase 2 ALPHA3 trial, seven of twelve patients were MRD-negative at Day 45, versus two of twelve controls — a 41.6 percentage point difference exceeding the 25–30% pre-specified clinically meaningful threshold. Lymphoma DNA in blood fell 97.7% in the cema-cel arm versus a 26.6% increase in the control arm. Full event-free survival data from ALPHA3 are expected mid-2027, with a potential BLA submission by late 2027 if results hold.
Caribou Biosciences is deploying CRISPR-based chRDNA editing. Their vispa-cel (CB-010) has produced efficacy in B-cell lymphoma “on par with autologous” (82% ORR, 64% CR, 51% 12-month PFS in a 22-patient confirmatory cohort), with the added feature of a PD-1 knockout to limit T-cell exhaustion — the first allogeneic CAR-T in the clinic with this design feature.
None of these programs are yet approved. Current allogeneic trials target hematologic malignancies; the CAR-T solid tumors application comes next. But the platform validation matters: if allogeneic CAR-T can match autologous in blood cancers, the technology and its dramatically lower manufacturing economics can then be applied to new antigens in solid tumors.
—
Engineering the Microenvironment
The TME problem requires biological engineering beyond antigen targeting and manufacturing. Several approaches are in early trials.
Chemokine receptor arming equips CAR-T cells with surface receptors (notably CXCR2) that respond to inflammatory chemokine gradients secreted within tumors, improving trafficking into the mass. Armored CAR-T cells co-secrete cytokines like IL-15 or IL-21 that maintain T-cell fitness in glucose-depleted, hypoxic environments. Logic-gated “AND” CAR constructs require two antigens to be present simultaneously before triggering activation, reducing off-tumor toxicity and enabling targeting of antigens shared with some normal tissues. Bispecific CAR constructs targeting both EGFR and B7-H3 are in early Phase I.
As of 2026, these approaches are mostly preclinical or in very early Phase I. No readout yet demonstrates that any single TME-engineering strategy crosses the efficacy threshold. The expectation within the field is that combinations — the right antigen target, the right allogeneic platform, the right TME-engineering payload — will be required rather than any single innovation.
—
Where This Leaves Us in 2026
Advancing CAR-T solid tumors therapeutics has not broken through broadly, but the question is no longer whether it will — it is where, in which tumor types, on which antigens, and at what cost.
The Lancet data from satri-cel establish that CAR-T can outperform standard of care in a solid tumor in a randomised trial. Afami-cel and lifileucel have demonstrated that engineered cell therapies can win FDA approval and generate commercial revenue in solid tumors. Allogeneic platforms have reached pivotal trials with compelling early efficacy signals, and the cost rationale for pursuing them is overwhelming.
The realistic clinical picture for CAR-T solid tumors over the next 24 to 36 months points to accelerated FDA approvals in narrow niches (GD2 neuroblastoma and B7-H3 in a highly pretreated indication are the most likely candidates), continued satri-cel regulatory progress in China, and pivotal allogeneic trial readouts that will determine whether off-the-shelf CAR-T can challenge autologous head-to-head.
The harder problems — TME penetration, antigen escape, durable responses in large heterogeneous populations — will take longer. Whether the next phase of this field, from clinical evidence to broad access, will be faster than the decade it took to get here remains the central open question.
—
This article was produced with AI assistance and reviewed by the editorial team.
3 thoughts on “CAR-T for Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem”